Trial Outcomes & Findings for Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma (NCT NCT01465464)
NCT ID: NCT01465464
Last Updated: 2019-08-07
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE3
Target enrollment
888 participants
Primary outcome timeframe
The time from the date of enrollment to the date of death from any cause, assessed up to three years after randomizationof the last patient
Results posted on
2019-08-07
Participant Flow
Participant milestones
| Measure |
Orantinib
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Overall Study
STARTED
|
444
|
444
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
444
|
444
|
Reasons for withdrawal
| Measure |
Orantinib
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Overall Study
Adverse Event
|
96
|
49
|
|
Overall Study
Lack of Efficacy
|
139
|
190
|
|
Overall Study
Physician Decision
|
13
|
5
|
|
Overall Study
Protocol Violation
|
1
|
1
|
|
Overall Study
Withdrawal by Subject
|
46
|
30
|
|
Overall Study
Other
|
9
|
3
|
|
Overall Study
Ongoing treatment at cutoff date
|
140
|
166
|
Baseline Characteristics
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Baseline characteristics by cohort
| Measure |
Orantinib
n=444 Participants
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
n=444 Participants
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
Total
n=888 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
189 Participants
n=99 Participants
|
202 Participants
n=107 Participants
|
391 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
255 Participants
n=99 Participants
|
242 Participants
n=107 Participants
|
497 Participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
81 Participants
n=99 Participants
|
80 Participants
n=107 Participants
|
161 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
363 Participants
n=99 Participants
|
364 Participants
n=107 Participants
|
727 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
444 Participants
n=99 Participants
|
444 Participants
n=107 Participants
|
888 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
South Korea
|
170 participants
n=99 Participants
|
170 participants
n=107 Participants
|
340 participants
n=206 Participants
|
|
Region of Enrollment
Japan
|
219 participants
n=99 Participants
|
213 participants
n=107 Participants
|
432 participants
n=206 Participants
|
|
Region of Enrollment
Taiwan
|
55 participants
n=99 Participants
|
61 participants
n=107 Participants
|
116 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: The time from the date of enrollment to the date of death from any cause, assessed up to three years after randomizationof the last patientPopulation: When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC. Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.
Outcome measures
| Measure |
Orantinib
n=168 Participants
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
n=163 Participants
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Overall Survival(OS)
|
946.0 days
Interval 807.0 to 1050.0
|
984.0 days
Interval 864.0 to
The upper limit of median OS didn't reach.
|
SECONDARY outcome
Timeframe: The time from the date of enrollment to the date of event for TACE discontinuation, assessed up to three years after randomizationof the last patientPopulation: When approximately 50% of the targeted number of time to TACE discontinuation events were confirmed, interim analysis was performed by IDMC. Because the Committee considered that significant results would no longer be obtained, the IDMC recommended to the Sponsor that the clinical trial would be discontinued, and the Sponsor stopped this trial.
Patients should not receive additional TACE therapy in this study after meeting any of the following conditions, at the Investigator's discretion. 1. The patient develops an intra-hepatic lesion that is uncontrolled by serial TACE 2. Deterioration in arterial pathways to treat HCC that makes additional TACE impossible 3. Severe vascular invasion occurs that makes additional TACE impossible 4. Extra hepatic spread considered relevant to life expectancy that requires another treatment modality for HCC 5. Liver function at grade Child-Pugh class C lasting for 28 days
Outcome measures
| Measure |
Orantinib
n=174 Participants
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
n=206 Participants
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Time to Transcatheter Arterial Chemoembolization (TACE) Failure
|
728.0 days
Interval 604.0 to 813.0
|
602.0 days
Interval 539.0 to 724.0
|
Adverse Events
Orantinib
Serious events: 200 serious events
Other events: 443 other events
Deaths: 33 deaths
Placebo
Serious events: 134 serious events
Other events: 436 other events
Deaths: 24 deaths
Serious adverse events
| Measure |
Orantinib
n=444 participants at risk
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
n=444 participants at risk
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Gastrointestinal disorders
Inguinal hernia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Blood and lymphatic system disorders
Anaemia
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Blood and lymphatic system disorders
Idiopathic thrombocytopenic purpura
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Acute pericarditis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Angina pectoris
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Atrial thrombosis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Cardiopulmonary arrest
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Heart failure
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Myocardial infarction
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Paroxysmal supraventricular tachycardia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Pericardial effusion
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Congenital, familial and genetic disorders
Hydrocele cord
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Eye disorders
Cataract
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Eye disorders
Cataract aggravated
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Eye disorders
Diabetic retinopathy
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Eye disorders
Retinal macroaneurysm
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Abdominal pain
|
2.0%
9/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.6%
7/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Acute pancreatitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Anal fistula
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Acute gastric ulcer with haemorrhage
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Ascites
|
4.3%
19/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
2.5%
11/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Colonic polyp
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Dental caries
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Diarrhea
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Duodenal ulcer hemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Epigastric pain
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Esophageal hemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Esophageal varices hemorrhage
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.6%
7/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastric varices bleeding
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastric varices haemorrhage
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.6%
7/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastroduodenal ulcer
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastroesophageal varices hemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastric perforation
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastrointestinal hemorrhage
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Incarcerated inguinal hernia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Ischemia bowel
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Ischemic enterocolitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Melaena
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Hematemesis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Intra-abdominal haemorrhage
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Nausea
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Oesophageal varices haemorrhage
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.6%
7/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Pancreatitis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Periodontal disease
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Right upper quadrant pain
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Ulcer duodenal haemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Upper gastrointestinal hemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Varices oesophageal
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Vomiting
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Condition aggravated
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Disease progression
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Edema limbs
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Fever
|
2.9%
13/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
2.5%
11/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Gait disturbance
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Malaise
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Multi organ failure
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Pain
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Weakness generalised
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Fatigue
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Acute cholecystitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Acute hepatic failure
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Biliary fistula
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Biloma
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Cholangitis
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Cholangitis acute
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Cholecystitis
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Dilatation intrahepatic duct acquired
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Gallbladder perforation
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Haemobilia
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatic failure
|
3.6%
16/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
2.5%
11/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatic function disorder
|
2.5%
11/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatic necrosis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatopathy
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hyperbilirubinemia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Jaundice
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Obstructive jaundice
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatic vein thrombosis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatorenal syndrome
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Immune system disorders
Contrast media allergy
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Acute bronchitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Acute gastroenteritis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Acute pyelonephritis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Appendicitis perforated
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Bacteremia
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Biliary tract infection
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Bronchopneumonia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Cellulitis of foot
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Cryptococcal pneumonitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Cystitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Enteritis infectious
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Hepatic infection bacterial
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Herpes zoster
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Infectious colitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Intra-abdominal infection
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Liver abscess
|
7.7%
34/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Otitis media chronic
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Periodontal abscess
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Pneumonia
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Pulpitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Rectal abscess
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Sepsis
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Spontaneous bacterial peritonitis
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Tuberculous pleurisy
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
UTI
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Upper respiratory infection
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Urinary tract infection
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Compression fracture
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Fall
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Fracture of lateral malleolus, closed
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Maternal exposure during pregnancy
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Nerve injury
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Operative haemorrhage
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Polytraumatism
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Post embolization syndrome
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Post procedural bile leak
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Injury, poisoning and procedural complications
Traffic accident
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
ALT increased
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
AST increased
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Blood bilirubin increased
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
CRP increased
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Creatinine increased
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Elevated liver enzymes
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Liver biopsy
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Spleen scan abnormal
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Platelet count decreased
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
WBC decreased
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Anorexia
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Diabetes mellitus aggravated
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Gout aggravated
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Hypokalaemia
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Inappetence
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Tumor lysis syndrome
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Cervical disc herniation
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Pain in thigh
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Pseudogout
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Wrist pain
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Avascular necrosis femoral head
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Spondylitis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone metastases
|
1.8%
8/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain metastases
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer of descending colon
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hemangioma
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma non-resectable
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatoma recurrent
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liver carcinoma ruptured
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung metastases
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal metastases
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor necrosis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor rupture
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of the gastrooesophageal junction
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of spinal cord
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cecal cancer
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inverting papilloma of the nasal cavity
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of cheek mucosa
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Schwannoma
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour embolism
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Cerebral infarction
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Hepatic encephalopathy
|
2.7%
12/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.4%
6/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Intracranial hemorrhage
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Numbness of lower extremities
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Spinal cord compression
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Syncope
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Dizziness
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Psychiatric disorders
Delirium
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Psychiatric disorders
Orientation disturbed
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Renal and urinary disorders
Acute kidney injury
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Renal and urinary disorders
Renal failure
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.90%
4/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Asphyxia
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration pneumonitis
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
COPD exacerbation
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Chronic cough
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
1.6%
7/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.45%
2/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Shortness of breath
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Skin and subcutaneous tissue disorders
Eczema nummular
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Skin and subcutaneous tissue disorders
Stevens-Johnson syndrome
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Surgical and medical procedures
Gastrooesophageal variceal haemorrhage prophylaxis
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Surgical and medical procedures
Induced abortion
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Surgical and medical procedures
Oesophageal variceal ligation
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.1%
5/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Varicose vein ruptured
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Abdominal aortic aneurysm
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Arterial stenosis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Obstructive arteriosclerosis of lower extremities
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Vascular disorder
|
0.00%
0/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.23%
1/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
Other adverse events
| Measure |
Orantinib
n=444 participants at risk
Orantinib (TSU-68): 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
|
Placebo
n=444 participants at risk
Placebo: 1 tablet was administered orally twice per day after meals, morning and evening.
|
|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
12.2%
54/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
7.2%
32/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Abdominal distension
|
11.3%
50/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
11.9%
53/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Abdominal pain
|
71.4%
317/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
65.8%
292/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Abdominal pain upper
|
12.6%
56/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
10.4%
46/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Ascites
|
31.5%
140/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
16.4%
73/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Constipation
|
40.3%
179/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
33.1%
147/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Diarrhoea
|
27.7%
123/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
15.8%
70/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Dyspepsia
|
11.5%
51/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
10.6%
47/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastritis
|
5.2%
23/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
6.5%
29/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
5.0%
22/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
3.2%
14/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Nausea
|
40.3%
179/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
40.3%
179/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Gastrointestinal disorders
Vomiting
|
28.4%
126/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
26.1%
116/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Chills
|
7.7%
34/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
5.2%
23/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Face oedema
|
31.1%
138/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
1.8%
8/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Fatigue
|
22.7%
101/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
20.7%
92/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Malaise
|
22.7%
101/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
19.4%
86/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Non-cardiac chest pain
|
7.2%
32/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
5.6%
25/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Oedema peripheral
|
29.3%
130/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
13.3%
59/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
General disorders
Pyrexia
|
59.5%
264/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
64.0%
284/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Hepatobiliary disorders
Hepatic failure
|
5.4%
24/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
4.5%
20/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Liver abscess
|
6.8%
30/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
0.68%
3/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Infections and infestations
Upper respiratory tract infection
|
19.4%
86/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
19.1%
85/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
ALT increased
|
45.0%
200/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
38.3%
170/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
AST increased
|
50.2%
223/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
42.6%
189/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
ALP increased
|
14.4%
64/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
5.0%
22/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Bilirubin increased
|
17.3%
77/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
16.9%
75/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
CRP increased
|
10.6%
47/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
9.9%
44/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Lymphocyte count decreased
|
9.0%
40/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
10.1%
45/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Platelet count decreased
|
11.9%
53/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
10.8%
48/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Investigations
Weight decreased
|
7.0%
31/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
4.5%
20/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Decreased appetite
|
47.1%
209/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
33.6%
149/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
5.2%
23/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
3.2%
14/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
22.1%
98/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
19.1%
85/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
7.7%
34/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
3.6%
16/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
7.0%
31/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
5.0%
22/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
7.7%
34/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
4.3%
19/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
20.3%
90/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
21.2%
94/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
8.6%
38/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
8.1%
36/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
7.2%
32/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
5.0%
22/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
9.0%
40/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
6.8%
30/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Dizziness
|
8.6%
38/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
7.9%
35/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Nervous system disorders
Headache
|
16.7%
74/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
14.0%
62/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Psychiatric disorders
Insomnia
|
17.8%
79/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
15.3%
68/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Renal and urinary disorders
Chromaturia
|
23.2%
103/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
4.1%
18/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Renal and urinary disorders
Proteinuria
|
10.6%
47/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
3.8%
17/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Vascular disorders
Hypertension
|
13.3%
59/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
12.8%
57/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
15.5%
69/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
15.3%
68/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
6.5%
29/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
6.8%
30/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
8.1%
36/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
3.6%
16/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
9.7%
43/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
11.5%
51/444 • From the date of the first treatment to 30 days after the last treatment
Main treatment discontinuation criteria * The Investigator concludes that the patients should be treated with another treatment modality except TACE for HCC * Patient has unacceptable/intolerable toxicities * Patient can not take both enhanced CT and enhanced MRI of the abdomen any more * Patient wishes to discontinue the treatment
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER